Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Metformin for Ki-67 in Endometrial Cancer
NCT03618472Completed
- Sponsor
- Ministry of Public Health
- Start
- Jul 2018
- Primary completion
- Nov 2019
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Randomised, double-blind trial of liquid metformin (Aspargo Labs) in endometrial cancer (EC) (2 arms), sponsored by Ministry of Public Health. Primary endpoint: Change of Ki-67 expression in endometrial tumor at 4 weeks. Started Jul 2018; status: completed.
02
Drugs
liquid metformin (Aspargo Labs)
03
Conditions
endometrial cancer (EC)
Beyond the preview
Go deeper on NCT03618472.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03618472.